AstraZeneca Secures Etcamah Breast Cancer Approval in Combination With CDK4/6 Inhibitors for US Patients

Etcamah breast cancer approval was reported on 4 September 2026, as the US Food and Drug Administration (FDA) cleared AstraZeneca’s camizestrant, sold under the brand name Etcamah, for use in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor in adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer. The clearance applies specifically to patients whose tumours develop an emergent ESR1 mutation while being treated with an aromatase inhibitor (AI) and a CDK4/6 inhibitor as first-line therapy, and it is contingent on detection of that mutation through an FDA-authorised test.

The three CDK4/6 inhibitors named on the new US label are abemaciclib, palbociclib and ribociclib, giving physicians the flexibility to keep patients on their existing CDK4/6 inhibitor while switching only the endocrine backbone to Etcamah once an ESR1 mutation appears. Because the approval targets molecular relapse rather than radiographic disease progression, it introduces a treatment strategy built around continuous circulating tumour DNA (ctDNA) monitoring rather than waiting for scans to show measurable tumour growth.

The accelerated approval rests on results from the pivotal SERENA-6 Phase III trial, first presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine. SERENA-6 enrolled 315 adult patients with histologically confirmed HR-positive, HER2-negative advanced breast cancer who were already receiving an AI plus a CDK4/6 inhibitor as first-line treatment, with progression-free survival (PFS) as its primary endpoint and overall survival (OS) and second progression-free survival (PFS2) as key secondary measures. This is the clinical foundation behind the Etcamah breast cancer approval now in effect across the US market.

Kevin Kalinsky, MD, MS, FASCO, Division Director of Medical Oncology at the Winship Cancer Institute of Emory University and a SERENA-6 investigator, described the approval as an important new option for the roughly one in three patients whose tumours develop ESR1 mutations before clinical or radiographic progression appears. He noted that clinicians can now change therapeutic strategy at an earlier point, “rather than waiting until the cancer becomes harder to treat,” preserving patient outcomes and quality of life.

The table below summarises the core regulatory and clinical details behind the Etcamah breast cancer approval for quick reference.

Learn More

AstraZeneca H1 2026 Results: Total Revenue Climbs to $30.7 Billion as Company Reaffirms $80 Billion 2030 Ambition

Etcamah Breast Cancer Approval Rests on SERENA-6 Trial Data

In a planned interim analysis of SERENA-6, the Etcamah combination reduced the risk of disease progression or death by 56% compared with standard-of-care treatment using an AI plus a CDK4/6 inhibitor. The hazard ratio was 0.44 (95% confidence interval: 0.31-0.60; p<0.00001), with median PFS reaching 16.0 months on the Etcamah arm versus 9.2 months on the AI arm.

Data for the key secondary endpoints were still developing at the time of the interim analysis. A later pre-planned analysis found a statistically significant and clinically meaningful PFS2 benefit of 25.7 months versus 19.1 months in favour of the Etcamah combination (hazard ratio: 0.63; 95% CI: 0.46-0.86; p=0.00373), and overall survival continued to trend in favour of switching to Etcamah (hazard ratio: 0.87; 95% CI: 0.57-1.30), though the trial will keep tracking OS as a key secondary endpoint. The table below lays out the full efficacy dataset supporting the Etcamah breast cancer approval.

Dave Fredrickson, Executive Vice President of the Oncology Haematology Business Unit at AstraZeneca, framed the decision as the company’s tenth FDA approval of the year and its fourth in breast cancer specifically. He described the Etcamah combination as reflecting AstraZeneca’s approach to redefining breast cancer care through ctDNA-guided treatment switching, calling it the first medicine of its kind approved in the first-line setting.

Learn More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

How the ctDNA-Guided Strategy Behind the Etcamah Breast Cancer Approval Works

Alongside the drug approval, the FDA cleared a companion diagnostic test designed to detect emerging ESR1 resistance mutations in the ctDNA of patients with HR-positive, HER2-negative advanced or metastatic breast cancer. SERENA-6 is described as the first global, double-blind, registrational Phase III trial to use a ctDNA-guided approach to catch endocrine resistance early and prompt a therapy switch before disease progression shows up on imaging.

The trial design called for blood-based ctDNA monitoring at the time of routine tumour scans, roughly every two to three months, to flag early signs of endocrine resistance through the emergence of ESR1 mutations. Once an ESR1 mutation was detected without accompanying disease progression, patients were switched from their AI to Etcamah while remaining on the same CDK4/6 inhibitor, preserving the rest of their treatment regimen. This ctDNA-guided switch is the mechanism underpinning the entire Etcamah breast cancer approval and distinguishes it from prior endocrine therapy approvals tied to radiographic progression.

The timeline below outlines how the ctDNA-guided monitoring and switching strategy unfolds in practice.

Etcamah Breast Cancer Approval Safety Profile and Disease Burden

The safety profile of Etcamah in combination with palbociclib, ribociclib or abemaciclib in SERENA-6 was consistent with the known safety profile of each individual medicine, and no new safety signals emerged. Treatment discontinuations were described as very low and similar across both study arms, a detail likely to reassure prescribers weighing an earlier switch in therapy under the new Etcamah breast cancer approval.

Breast cancer remains the most common cancer among women in the US, with more than 300,000 new diagnoses and more than 42,000 deaths each year. Roughly 37,000 patients with HR-positive metastatic breast cancer in the US receive a first-line medicine, most often an endocrine therapy paired with a CDK4/6 inhibitor, yet resistance frequently develops, after which treatment options narrow and survival rates decline. ESR1 mutations, a key driver of that resistance, emerge in about 30% of patients with endocrine-sensitive HR-positive disease during first-line treatment, often before disease progression is otherwise detectable.

That resistance pattern is precisely the gap the Etcamah breast cancer approval is designed to close. Once ESR1 mutations take hold, patients historically had to wait for imaging to confirm measurable progression before oncologists could justify a change in therapy, a delay that allowed resistant tumour clones additional time to expand. By authorising a companion diagnostic alongside the drug itself, the FDA has effectively endorsed molecular monitoring as a trigger point in its own right, a shift that could influence how other endocrine-resistant cancers are managed going forward.

The table below summarises the US and global disease burden context relevant to the Etcamah breast cancer approval.